MedTrace Logo

Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers

NCT00475202 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2007-05-21

No results posted yet for this study

Summary

Diabetic foot ulcers are a major cause of morbidity and mortality, accounting for approximately two-thirds of all non-traumatic amputations performed in the United States. The cost of foot ulcers in diabetic patients averages almost $28,000 for the two years after diagnosis of the ulcer. Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a diverse range of medical conditions. HBO also has been used as an adjunct to antibiotics, debridement, and revascularization in the therapy of chronic, nonhealing wounds associated with diabetes or non-diabetic vascular insufficiency.

The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients with foot ulcers.

Conditions

  • Diabetic Foot Ulcers
  • Hyperbaric Therapy
  • Angiogenesis

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Albert Rabinovitz, MD · Assaf-Harofeh Medical Center

  • Efrati Shai, MD · Assaf-Harofeh Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00475202 on ClinicalTrials.gov